DK0801564T3 - Anvendelse af nebivolol som et antiatherogent middel - Google Patents

Anvendelse af nebivolol som et antiatherogent middel

Info

Publication number
DK0801564T3
DK0801564T3 DK95942209T DK95942209T DK0801564T3 DK 0801564 T3 DK0801564 T3 DK 0801564T3 DK 95942209 T DK95942209 T DK 95942209T DK 95942209 T DK95942209 T DK 95942209T DK 0801564 T3 DK0801564 T3 DK 0801564T3
Authority
DK
Denmark
Prior art keywords
nebivolol
alpha
antiatherogenic
agent
antiatherogenic agent
Prior art date
Application number
DK95942209T
Other languages
English (en)
Inventor
Chaffoy De Courcelles Didie De
Anne Simone Josephine Lesage
Josepha Eduarda Maria F Leysen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK0801564T3 publication Critical patent/DK0801564T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
DK95942209T 1994-12-28 1995-12-21 Anvendelse af nebivolol som et antiatherogent middel DK0801564T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28
PCT/EP1995/005174 WO1996019987A1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic

Publications (1)

Publication Number Publication Date
DK0801564T3 true DK0801564T3 (da) 2002-07-15

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95942209T DK0801564T3 (da) 1994-12-28 1995-12-21 Anvendelse af nebivolol som et antiatherogent middel

Country Status (20)

Country Link
US (2) US5874461A (da)
EP (1) EP0801564B1 (da)
JP (1) JPH10511655A (da)
KR (1) KR100264348B1 (da)
CN (1) CN1167418C (da)
AT (1) ATE214924T1 (da)
AU (1) AU700364B2 (da)
CA (1) CA2207333C (da)
CZ (1) CZ287513B6 (da)
DE (1) DE69526120T2 (da)
DK (1) DK0801564T3 (da)
ES (1) ES2176354T3 (da)
FI (1) FI118884B (da)
HU (1) HU226208B1 (da)
NO (1) NO315687B1 (da)
NZ (1) NZ298074A (da)
PT (1) PT801564E (da)
SI (1) SI0801564T1 (da)
SK (1) SK282144B6 (da)
WO (1) WO1996019987A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0801564T1 (en) * 1994-12-28 2002-08-31 Janssen Pharmaceutica N.V. Use of nebivolol as an anti-atherogenic
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
AU2002338528B2 (en) * 2001-05-02 2008-01-24 Nicox S.A. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
EP1558922B1 (en) * 2002-10-30 2013-02-27 Ampere Life Sciences, Inc. Identifying therapeutic compounds based on their physical-chemical properties
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005032544A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Treatment of mitochondrial diseases
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP1737847B1 (en) 2004-07-30 2008-06-04 Torrent Pharmaceuticals Ltd Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
EP1848424B1 (en) * 2005-01-31 2017-04-05 Mylan Laboratories, Inc Pharmaceutical composition comprising hydroxylated nebivolol
EP2471530B1 (en) 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2635280C (en) 2006-02-22 2017-12-12 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009061744A2 (en) 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
EP2262508B1 (en) 2008-03-05 2018-10-03 BioElectron Technology Corporation SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2010030607A1 (en) 2008-09-10 2010-03-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
JP5719309B2 (ja) * 2008-12-19 2015-05-13 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 哺乳動物細胞培養用の栄養補助剤及び使用方法
DK2424495T3 (da) 2009-04-28 2018-04-30 Bioelectron Tech Corp Behandling af lebers arvelig optisk neuropati og dominant optisk atrofi med tocotrienol-quinoner
WO2011150859A1 (en) * 2010-06-04 2011-12-08 Comprehensive Drug Enterprises Ltd Oral meclizine aqueous formulations with taste flavoring agent
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
TW201615191A (zh) * 2014-10-24 2016-05-01 朗齊生物醫學股份有限公司 氨氯地平藥物應用於癌症治療
KR102626895B1 (ko) 2014-12-16 2024-01-18 피티씨 테라퓨틱스, 인크. (r)-2-하이드록시-2-메틸-4-(2,4,5-트리메틸-3,6-디옥소사이클로헥사-1,4-디에닐)부탄아미드의 다형성 및 무정형 형태
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
SI0801564T1 (en) * 1994-12-28 2002-08-31 Janssen Pharmaceutica N.V. Use of nebivolol as an anti-atherogenic

Also Published As

Publication number Publication date
NO972980D0 (no) 1997-06-26
EP0801564B1 (en) 2002-03-27
WO1996019987A1 (en) 1996-07-04
ES2176354T3 (es) 2002-12-01
HU226208B1 (en) 2008-06-30
SI0801564T1 (en) 2002-08-31
NO972980L (no) 1997-06-26
AU4347796A (en) 1996-07-19
MX9704669A (es) 1997-09-30
PT801564E (pt) 2002-09-30
US6075046A (en) 2000-06-13
CA2207333C (en) 2006-10-17
SK282144B6 (sk) 2001-11-06
EP0801564A1 (en) 1997-10-22
CN1171739A (zh) 1998-01-28
CZ287513B6 (en) 2000-12-13
FI972793A (fi) 1997-06-27
CN1167418C (zh) 2004-09-22
KR100264348B1 (ko) 2000-08-16
ATE214924T1 (de) 2002-04-15
AU700364B2 (en) 1999-01-07
DE69526120D1 (de) 2002-05-02
CA2207333A1 (en) 1996-07-04
JPH10511655A (ja) 1998-11-10
US5874461A (en) 1999-02-23
FI118884B (fi) 2008-04-30
FI972793A0 (fi) 1997-06-27
NZ298074A (en) 2001-01-26
CZ191997A3 (cs) 1999-01-13
SK85697A3 (en) 2000-04-10
HUT77927A (hu) 1998-11-30
NO315687B1 (no) 2003-10-13
DE69526120T2 (de) 2002-11-28

Similar Documents

Publication Publication Date Title
DK0801564T3 (da) Anvendelse af nebivolol som et antiatherogent middel
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
NO986051L (no) Anvendelsen av topiramat eller derivater derav for fremstilling av et medikament for behandling av manisk depressive, bipolare forstyrrelser
DK0966447T3 (da) Anvendelige små molekyler til behandling af betændelsessygdomme
DK0932398T3 (da) Anvendelse af topiramat eller derivater deraf til fremstilling af et lægemiddel til behandling af maniodepressive bipolære forstyrrelser
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
DK0888327T3 (da) Benzopyranderivater, som har antagonistisk virkning imod leukotriener
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
BG105264A (en) New use of taxoid derivatives
BG102707A (en) New triazolopurinpurines, method for their preparation and appplication as medicamentous forms
DE69309790D1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-Furyl)-3-Derivate und pharmazeutische Präparate davon, zur Behandlung von Kardiovaskulär-Erkrankungen
EA199700243A1 (ru) Производное аминотетралина для лечения сердечно-сосудистых заболеваний
NO990450D0 (no) Behandling av sinnslidelser
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
NO984651L (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
BR9813098A (pt) Uso de glicosaminoglicans, preparação farmacêutica, e, combinaçào
MX9706454A (es) Uso de benzotiazoles fusionados como neuroproyectores.